Archer Investment Corp bought a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 8,262 shares of the company's stock, valued at approximately $9,909,000. Eli Lilly and Company comprises approximately 1.5% of Archer Investment Corp's portfolio, making the stock its 11th largest position.
Several other institutional investors also recently bought and sold shares of LLY. Willner & Heller LLC raised its holdings in Eli Lilly and Company by 1.0% during the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company's stock valued at $1,100,000 after buying an additional 9 shares during the last quarter. Aspiring Ventures LLC grew its holdings in Eli Lilly and Company by 3.7% in the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock worth $306,000 after acquiring an additional 9 shares during the last quarter. Wealthspan Partners LLC grew its holdings in Eli Lilly and Company by 0.4% in the 2nd quarter. Wealthspan Partners LLC now owns 2,120 shares of the company's stock worth $2,543,000 after acquiring an additional 9 shares during the last quarter. Navigoe LLC boosted its holdings in shares of Eli Lilly and Company by 8.7% during the second quarter. Navigoe LLC now owns 113 shares of the company's stock worth $135,000 after purchasing an additional 9 shares during the period. Finally, Dudley Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 0.7% during the fourth quarter. Dudley Capital Management LLC now owns 1,475 shares of the company's stock worth $1,585,000 after purchasing an additional 10 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Merida acquisition expands Lilly’s pipeline: Lilly agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash. The deal adds antibody-engineering capabilities and precision therapies targeting autoimmune and allergic diseases, including Phase 1 candidate MER511 for Graves’ disease and thyroid eye disease. Investors may view the transaction as a long-term diversification move that reduces reliance on GLP-1 medicines. Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
- Positive Sentiment: Zepbound and regulatory developments support the core franchise: A new Zepbound study was presented as potentially favorable for Lilly investors, while a recent FDA action could give Lilly stronger evidence in negotiations with insurers and employers over coverage of certain GLP-1 treatments. These developments may help defend demand as some payers reconsider coverage heading into 2027. Insurers Are Pulling Back From GLP-1 Drugs
- Positive Sentiment: Strong earnings and pipeline optimism remain supportive: Lilly recently reported revenue growth of 47.7% year over year and earnings well above consensus estimates. Analysts and financial commentary continue to highlight the company’s broad pipeline and potential for further growth, with valuation viewed by some investors as attractive relative to its longer-term opportunity. Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity
- Neutral Sentiment: Near-term uncertainty centers on Merida execution: Merida’s lead drug is still in Phase 1, and much of the purchase price depends on future milestones. The acquisition could create substantial value, but clinical, regulatory and integration risks remain. Lilly is scheduled to participate in the Morgan Stanley Global Healthcare Conference on September 14, which could provide additional strategy or pipeline commentary. Lilly’s $2.88 Billion Immunology Deal Starts in Phase 1
Insider Activity
In related news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on LLY shares. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 23rd. Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a research report on Thursday, June 25th. Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Finally, Citigroup upped their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,292.18.
Get Our Latest Report on Eli Lilly and Company
Eli Lilly and Company Stock Up 0.0%
LLY stock opened at $1,160.52 on Thursday. The business has a 50 day moving average of $1,192.23 and a 200 day moving average of $1,068.27. The firm has a market cap of $1.09 trillion, a PE ratio of 38.94, a price-to-earnings-growth ratio of 1.44 and a beta of 0.50. Eli Lilly and Company has a twelve month low of $712.05 and a twelve month high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the company posted $6.31 earnings per share. The company's revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is currently 23.22%.
Eli Lilly and Company Company Profile
(
Free Report)
Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
